# Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

> **NCT00694096** · PHASE1 · COMPLETED · sponsor: **University of Utah** · enrollment: 25 (actual)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00694096
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694096, "Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00694096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*